Tourmaline Bio, Inc. - Common Stock (TRML)

TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024.

TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the first quarter of 2024.

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose 0.84% to 16,506.28. The S&P 500 also rose, gaining, 0.53% to 5,252.23.

Tourmaline Bio just reported results for the fourth quarter of 2023.

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a preliminary non-binding acquisition offer.

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition news.

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.